tiprankstipranks
Trending News
More News >
Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
Hong Kong Market
Advertisement

Hansoh Pharmaceutical Group Company Limited (3692) Stock Statistics & Valuation Metrics

Compare
6 Followers

Total Valuation

Hansoh Pharmaceutical Group Company Limited has a market cap or net worth of HK$234.58B. The enterprise value is HK$147.62B.
Market CapHK$234.58B
Enterprise ValueHK$147.62B

Share Statistics

Hansoh Pharmaceutical Group Company Limited has 6,055,150,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,055,150,000
Owned by Insiders
Owned by Institutions

Financial Efficiency

Hansoh Pharmaceutical Group Company Limited’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 11.94%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)11.94%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.36M
Profits Per Employee486.35K
Employee Count8,989
Asset Turnover0.39
Inventory Turnover1.70

Valuation Ratios

The current PE Ratio of Hansoh Pharmaceutical Group Company Limited is 44.4. Hansoh Pharmaceutical Group Company Limited’s PEG ratio is 0.46.
PE Ratio44.4
PS Ratio7.85
PB Ratio3.36
Price to Fair Value3.36
Price to FCF26.44
Price to Operating Cash Flow175.20
PEG Ratio0.46

Income Statement

In the last 12 months, Hansoh Pharmaceutical Group Company Limited had revenue of 12.26B and earned 4.37B in profits. Earnings per share was 0.74.
Revenue12.26B
Gross Profit11.16B
Operating Income4.03B
Pretax Income5.09B
Net Income4.37B
EBITDA4.28B
Earnings Per Share (EPS)0.74

Cash Flow

In the last 12 months, operating cash flow was 1.18B and capital expenditures -120.12M, giving a free cash flow of 1.06B billion.
Operating Cash Flow1.18B
Free Cash Flow1.06B
Free Cash Flow per Share0.18

Dividends & Yields

Hansoh Pharmaceutical Group Company Limited pays an annual dividend of HK$0.232, resulting in a dividend yield of 0.95%
Dividend Per ShareHK$0.232
Dividend Yield0.95%
Payout Ratio26.17%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.77
52-Week Price Change89.72%
50-Day Moving Average36.23
200-Day Moving Average26.06
Relative Strength Index (RSI)63.12
Average Volume (3m)12.35M

Important Dates

Hansoh Pharmaceutical Group Company Limited upcoming earnings date is Mar 31, 2026, TBA (Confirmed).
Last Earnings DateAug 18, 2025
Next Earnings DateMar 31, 2026
Ex-Dividend DateSep 22, 2025

Financial Position

Hansoh Pharmaceutical Group Company Limited as a current ratio of 10.18, with Debt / Equity ratio of 0.38%
Current Ratio10.18
Quick Ratio9.94
Debt to Market Cap<0.01
Net Debt to EBITDA-5.26
Interest Coverage Ratio602.65

Taxes

In the past 12 months, Hansoh Pharmaceutical Group Company Limited has paid 713.36M in taxes.
Income Tax713.36M
Effective Tax Rate0.14

Enterprise Valuation

Hansoh Pharmaceutical Group Company Limited EV to EBITDA ratio is 17.24, with an EV/FCF ratio of 20.26.
EV to Sales6.01
EV to EBITDA17.24
EV to Free Cash Flow20.26
EV to Operating Cash Flow19.09

Balance Sheet

Hansoh Pharmaceutical Group Company Limited has HK$27.12B in cash and marketable securities with HK$116.86M in debt, giving a net cash position of HK$27.00B billion.
Cash & Marketable SecuritiesHK$27.12B
Total DebtHK$116.86M
Net CashHK$27.00B
Net Cash Per ShareHK$4.46
Tangible Book Value Per ShareHK$4.79

Margins

Gross margin is 90.84%, with operating margin of 32.88%, and net profit margin of 35.66%.
Gross Margin90.84%
Operating Margin32.88%
Pretax Margin41.48%
Net Profit Margin35.66%
EBITDA Margin34.89%
EBIT Margin31.83%

Analyst Forecast

The average price target for Hansoh Pharmaceutical Group Company Limited is HK$42.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$42.10
Price Target Upside8.67% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast8.68%
EPS Growth Forecast0.82%

Scores

Smart Score9
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis